IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-56675-3.html
   My bibliography  Save this article

PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma

Author

Listed:
  • Valentin Van den bossche

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain
    King Albert II Cancer Institute, Department of Medical Oncology, Cliniques Universitaires Saint-Luc)

  • Julie Vignau

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Engy Vigneron

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Isabella Rizzi

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Hannah Zaryouh

    (Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp)

  • An Wouters

    (Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp)

  • Jérôme Ambroise

    (Centre des Technologies Moléculaires Appliquées (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Steven Van Laere

    (GZA Ziekenhuizen)

  • Simon Beyaert

    (King Albert II Cancer Institute, Department of Medical Oncology, Cliniques Universitaires Saint-Luc
    Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain
    Department of Head and Neck Surgery, Cliniques Universitaires Saint-Luc)

  • Raphaël Helaers

    (UCLouvain)

  • Cédric van Marcke

    (King Albert II Cancer Institute, Department of Medical Oncology, Cliniques Universitaires Saint-Luc
    Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Lionel Mignion

    (UCLouvain)

  • Elise Y. Lepicard

    (UCLouvain)

  • Bénédicte F. Jordan

    (UCLouvain)

  • Céline Guilbaud

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Olivier Lowyck

    (King Albert II Cancer Institute, Department of Medical Oncology, Cliniques Universitaires Saint-Luc
    Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Hajar Dahou

    (Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Antonella Mendola

    (Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Manon Desgres

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Léo Aubert

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain)

  • Isabelle Gerin

    (UCLouvain)

  • Guido T. Bommer

    (UCLouvain)

  • Romain Boidot

    (Georges‑François Leclerc Cancer Center‑UNICANCER
    ICMUB UMR CNRS 6302)

  • Perrine Vermonden

    (Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain)

  • Aurélien Warnant

    (Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain)

  • Yvan Larondelle

    (Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain)

  • Jean-Pascal Machiels

    (King Albert II Cancer Institute, Department of Medical Oncology, Cliniques Universitaires Saint-Luc
    Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain
    Department of Head and Neck Surgery, Cliniques Universitaires Saint-Luc)

  • Olivier Feron

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain
    WEL Research Institute)

  • Sandra Schmitz

    (King Albert II Cancer Institute, Department of Medical Oncology, Cliniques Universitaires Saint-Luc
    Pole of Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain
    Department of Head and Neck Surgery, Cliniques Universitaires Saint-Luc)

  • Cyril Corbet

    (Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain
    WEL Research Institute)

Abstract

Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent occurrence of secondary resistance mechanisms. Here we report that cetuximab-resistant HNSCC cells display a peroxisome proliferator-activated receptor alpha (PPARα)-mediated lipid metabolism reprogramming, with increased fatty acid uptake and oxidation capacities, while glycolysis is not modified. This metabolic shift makes cetuximab-resistant HNSCC cells particularly sensitive to a pharmacological inhibition of either carnitine palmitoyltransferase 1A (CPT1A) or PPARα in 3D spheroids and tumor xenografts in mice. Importantly, the PPARα-related gene signature, in human clinical datasets, correlates with lower response to anti-EGFR therapy and poor survival in HNSCC patients, thereby validating its clinical relevance. This study points out lipid metabolism rewiring as a non-genetic resistance-causing mechanism in HNSCC that may be therapeutically targeted to overcome acquired resistance to anti-EGFR therapy.

Suggested Citation

  • Valentin Van den bossche & Julie Vignau & Engy Vigneron & Isabella Rizzi & Hannah Zaryouh & An Wouters & Jérôme Ambroise & Steven Van Laere & Simon Beyaert & Raphaël Helaers & Cédric van Marcke & Lion, 2025. "PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma," Nature Communications, Nature, vol. 16(1), pages 1-21, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56675-3
    DOI: 10.1038/s41467-025-56675-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-56675-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-56675-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56675-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.